{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:21:35Z","timestamp":1784035295093,"version":"3.55.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,17]]},"DOI":"10.7759\/cureus.79178","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:53:41Z","timestamp":1739822021000},"source":"Crossref","is-referenced-by-count":1,"title":["A Severe Case of Nuclear Matrix Protein-2-Positive Dermatomyositis With Negative Malignancy Workup"],"prefix":"10.7759","author":[{"given":"Shreya","family":"Kondle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Dermatomyositis","author":"Qudsiya Z","year":"2023","unstructured":"Qudsiya Z, Waseem M. Dermatomyositis. StatPearls. StatPearls Publishing, Treasure Island, FL; 2023."},{"key":"ref2","article-title":"Clinical and serological characterization of the anti-MJ antibody in childhood myositis","volume":"40","author":"Oddis CV","year":"1997","unstructured":"Oddis CV, Fertig N, Goel A, et al.. Clinical and serological characterization of the anti-MJ antibody in childhood myositis. Arthritis Rheum. 1997, 40:139.","journal-title":"Arthritis Rheum"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/art.24547","article-title":"Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis","volume":"60","author":"Gunawardena H","year":"2009","unstructured":"Gunawardena H, Wedderburn LR, Chinoy H, et al.. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum. 2009, 60:1807-14. 10.1002\/art.24547","journal-title":"Arthritis Rheum"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090461","article-title":"Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein","volume":"36","author":"Espada G","year":"2009","unstructured":"Espada G, Maldonado Cocco JA, Fertig N, Oddis CV. Clinical and serologic characterization of an Argentine pediatric myositis cohort: identification of a novel autoantibody (anti-MJ) to a 142-kDa protein. J Rheumatol. 2009, 36:2547-51. 10.3899\/jrheum.090461","journal-title":"J Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/art.38093","article-title":"Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3","volume":"65","author":"Fiorentino DF","year":"2013","unstructured":"Fiorentino DF, Chung LS, Christopher-Stine L, et al.. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1\u03b3. Arthritis Rheum. 2013, 65:2954-62. 10.1002\/art.38093","journal-title":"Arthritis Rheum"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23188","article-title":"Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients","volume":"69","author":"Albayda J","year":"2017","unstructured":"Albayda J, Pinal-Fernandez I, Huang W, et al.. Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken). 2017, 69:1771-6. 10.1002\/acr.23188","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.141443","article-title":"The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from dermatomyositis patients","volume":"42","author":"Pinal-Fernandez I","year":"2015","unstructured":"Pinal-Fernandez I, Casciola-Rosen LA, Christopher-Stine L, Corse AM, Mammen AL. The prevalence of individual histopathologic features varies according to autoantibody status in muscle biopsies from dermatomyositis patients. J Rheumatol. 2015, 42:1448-54.","journal-title":"J Rheumatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rap\/rkad066","article-title":"Nuclear matrix protein 2 antibody-positive dermatomyositis associated with hepatocellular carcinoma","volume":"7","author":"Ueda Y","year":"2023","unstructured":"Ueda Y, Shimada K. Nuclear matrix protein 2 antibody-positive dermatomyositis associated with hepatocellular carcinoma. Rheumatol Adv Pract. 2023, 7:rkad066. 10.1093\/rap\/rkad066","journal-title":"Rheumatol Adv Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08922-4","article-title":"Autoantibody markers of increased risk of malignancy in patients with dermatomyositis","volume":"63","author":"Marz\u0119cka M","year":"2022","unstructured":"Marz\u0119cka M, Niemczyk A, Rudnicka L. Autoantibody markers of increased risk of malignancy in patients with dermatomyositis. Clin Rev Allergy Immunol. 2022, 63:289-96. 10.1007\/s12016-022-08922-4","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurpra.2014.07.020","article-title":"Dermatomyositis","volume":"10","author":"Ruhlman D","year":"2014","unstructured":"Ruhlman D, Otten C, Colella C. Dermatomyositis. J Nurse Pract. 2014, 10:674-81. 10.1016\/j.nurpra.2014.07.020","journal-title":"J Nurse Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.8884","article-title":"Anti-nuclear matrix protein 2 antibody-positive amyopathic dermatomyositis presenting in a patient with prostate cancer: a case report","volume":"12","author":"Shan DM","year":"2024","unstructured":"Shan DM, Gupta N, Ortega-Loayza AG, Shea S, Nandan A. Anti-nuclear matrix protein 2 antibody-positive amyopathic dermatomyositis presenting in a patient with prostate cancer: a case report. Clin Case Rep. 2024, 12:e8884. 10.1002\/ccr3.8884","journal-title":"Clin Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal R","year":"2022","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J, et al.. Trial of intravenous immune globulin in dermatomyositis. N Engl J Med. 2022, 387:1264-78. 10.1056\/NEJMoa2117912","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/art.30513","article-title":"Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients","volume":"63","author":"Marie I","year":"2011","unstructured":"Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. 2011, 63:3439-47. 10.1002\/art.30513","journal-title":"Arthritis Rheum"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/334525-a-severe-case-of-nuclear-matrix-protein-2-positive-dermatomyositis-with-negative-malignancy-workup","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:53:42Z","timestamp":1739822022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/334525-a-severe-case-of-nuclear-matrix-protein-2-positive-dermatomyositis-with-negative-malignancy-workup"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.79178","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,17]]}}}